Prolia family (denosumab for osteoporosis) — J0897, Q5136, Q5157, Q5158

About Prolia & the denosumab molecule FDA labels verified May 2026

Denosumab is a fully human IgG2 monoclonal antibody against RANK ligand (RANKL). By binding RANKL, denosumab prevents activation of osteoclasts — the cells responsible for bone resorption.

Prolia (Amgen) is the FDA-approved denosumab product for osteoporosis and cancer-treatment-induced bone loss, dosed at 60 mg subcutaneously every 6 months. The same molecule is sold by Amgen as Xgeva for prevention of skeletal-related events in cancer patients (bone metastases from solid tumors, multiple myeloma, giant-cell tumor of bone, hypercalcemia of malignancy) at 120 mg subcutaneously every 4 weeks. Although both products bill under the same HCPCS J0897 ("Injection, denosumab, 1 mg"), they are not clinically interchangeable: the FDA-approved indications, doses, dosing intervals, and biosimilar pairings differ.

The first FDA-approved Prolia biosimilar, Jubbonti (denosumab-bbdz, Sandoz), was approved in March 2024 with an interchangeability designation. The same Sandoz molecule is sold as Wyost for the Xgeva (cancer SRE) indication — identical molecule, separately FDA-approved as different brands for different indications. Subsequent Prolia biosimilars include Stoboclo (denosumab-bmwo, Celltrion) and denosumab-bnht (Q5158).

Prolia vs. Xgeva — the same molecule, two products FDA labels verified May 2026

This is the highest-stakes disambiguation on the denosumab page. Mis-billing across the line is a frequent audit finding because both products share HCPCS J0897.

Four-product Prolia biosimilar family CMS HCPCS + FDA verified May 2026

Reference plus three biosimilars. Jubbonti was the first FDA-approved Prolia biosimilar (March 2024) with interchangeability. All four codes use 1 unit = 1 mg, and all ship as 60 mg / 1 mL single-use prefilled syringes.

All four products share the same molecular structure, the same Warnings & Precautions, and the same co-therapy (calcium ≥ 1,000 mg/day + vitamin D ≥ 400 IU/day during treatment). Pre-treatment workup and monitoring requirements are identical across the family.

Dosing, pre-treatment workup, and co-therapy FDA Prolia label + AACE/Endocrine Society 2025

60 mg subcutaneously every 6 months. The pre-treatment workup is the dominant clinical-policy hurdle for prior-authorization approval.

Standard regimen

• Dose: 60 mg SC every 6 months (twice yearly)
• Site: upper arm, upper thigh, or abdomen
• Form: single-use 60 mg / 1 mL prefilled syringe (no reconstitution, no IV push)
• Schedule: if a dose is missed, administer as soon as possible; thereafter, schedule at every 6 months from the date of the last injection
• Co-therapy (FDA label): calcium ≥ 1,000 mg/day + vitamin D ≥ 400 IU/day during therapy — not optional

Pre-treatment workup checklist

Document each item before submitting the prior authorization. Most denials trace to one of these missing pieces.

• DXA scan with documented T-score (≤ -2.5 supports the postmenopausal/male osteoporosis indication; less restrictive for AI/ADT-induced bone loss)
• Serum calcium + 25-OH vitamin D — correct deficiency before initiation
• Renal function (CrCl) — CrCl < 30 mL/min and dialysis patients are at substantially higher hypocalcemia risk; monitor calcium more closely
• Dental evaluation — complete invasive dental procedures (extractions, implants) before initiation when feasible (MRONJ risk)
• Pregnancy testing if applicable (denosumab is contraindicated in pregnancy — embryo-fetal toxicity)
• History of fracture risk: prior osteoporotic fracture, glucocorticoid exposure (≥ 7.5 mg/day prednisone-equivalent ≥ 6 months), aromatase-inhibitor / ADT therapy, multiple risk factors
• Step-therapy documentation when required: trial of (or contraindication to) oral bisphosphonates (alendronate, risedronate)

Indications & eligibility

• Postmenopausal women with osteoporosis at high fracture risk (T-score ≤ -2.5 OR history of osteoporotic fracture OR multiple risk factors OR failed/intolerant of other osteoporosis therapies)
• Increase bone mass in men with osteoporosis at high fracture risk
• Glucocorticoid-induced osteoporosis in men + women on or initiating systemic glucocorticoids ≥ 7.5 mg/day prednisone-equivalent for ≥ 6 months at high fracture risk
• Treatment-induced bone loss in women with breast cancer receiving aromatase inhibitor therapy at high fracture risk
• Treatment-induced bone loss in men with non-metastatic prostate cancer receiving androgen deprivation therapy at high fracture risk

NDC reference — all four products FDA NDC Directory verified May 2026

All four products ship as 60 mg / 1 mL single-use prefilled syringes. Pad to 11 digits with leading zero in the labeler segment for CMS-1500 Box 24A. NDCs below reflect manufacturer billing references; verify against the actual carton at billing time, especially for newer biosimilars.

Prolia (J0897) — Amgen labeler 55513

Jubbonti (Q5136) — Sandoz

Stoboclo (Q5157) — Celltrion

denosumab-bnht (Q5158)

Administration codes CPT verified May 2026

Prolia is a non-chemotherapeutic subcutaneous injection. Use 96372 — do NOT use 96401 (chemo SC) and do NOT use 96365/96413 (IV codes).

Why 96372 — non-chemo SC therapeutic injection

For the osteoporosis indication, denosumab is administered as a single subcutaneous injection from a prefilled syringe. The injection meets the CPT 96372 definition: "therapeutic, prophylactic, or diagnostic injection (specify substance); subcutaneous or intramuscular." There is no infusion time, no observation period beyond standard practice, and no chemotherapy classification — this is a non-cancer anti-resorptive given for bone-density preservation.

A few payers have historically accepted 96401 for AI-induced or ADT-induced bone loss because the underlying diagnosis is cancer-related, but the FDA-approved Prolia indication is "treatment-induced bone loss," not cancer treatment per se — 96372 remains the correct code. If a payer's claims-edit system rejects 96372 for an oncology-history patient, appeal with the Prolia FDA label and CPT manual definition rather than recoding to 96401.

Modifiers — JZ standard, JW rare CMS verified May 2026

Prefilled-syringe products at matched dose almost never trigger waste. JZ is the dominant modifier; JW is rare and only applies if a syringe is broken or contaminated before delivery.

JZ — required when no drug discarded

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. For Prolia, JZ applies on every standard 60 mg dose — the 60 mg prefilled syringe is administered in full with no waste. Append JZ to the J0897 / Q5136 / Q5157 / Q5158 line.

JW — only if drug discarded

JW is rare for Prolia because the dose is matched to the prefilled syringe. JW would apply only if a syringe was broken, contaminated, or unable to be administered — in which case bill the discarded units on a separate line with JW and document the circumstance. CMS requires the wastage be documented in the medical record.

Modifier 25 — same-day E/M

Append modifier 25 to the same-day E/M code if a significant, separately identifiable evaluation occurred (DXA review, fracture-risk reassessment, treatment-decision encounter). Routine pre-injection check-in is bundled into the 96372 administration code.

ICD-10-CM diagnosis matrix — multi-indication FY2026 verified May 2026

Use the most specific code supported by chart documentation. Each Prolia indication has a distinct ICD-10 family. Pair primary diagnosis with secondary codes (long-term medication therapy, hormonal therapy, oncology history) where applicable.

Site of care & place of service Verified May 2026

SC injection from prefilled syringe fits any office or clinic setting cleanly. POS 11 (office) is the dominant Prolia site of care.

Claim form field mapping Manufacturer + payer billing PDFs

CMS-1500 / 837P (physician office, POS 11) example for a 60 mg Prolia dose.

Source: Amgen Assist 360 Prolia Reimbursement Guide; Sandoz One Source Jubbonti billing reference; Celltrion Connect Stoboclo billing reference.

Payer policies + CMS LCD L33394 Reviewed May 2026

Medicare Part B covers denosumab for osteoporosis under Local Coverage Determination L33394 (and parallel articles in other MAC jurisdictions). Commercial payers add step therapy and biosimilar-preferred designations.

CMS LCD L33394 — Drugs and Biologicals (osteoporosis)

LCD L33394 is applied by several MACs to osteoporosis injectables, including denosumab (J0897) and zoledronic acid (J3489 / Q5101 biosimilars). Coverage criteria typically require:

• Documented diagnosis of osteoporosis (DXA T-score ≤ -2.5) OR history of osteoporotic fracture OR multiple fracture risk factors OR documented high fracture risk from secondary cause (glucocorticoid, AI, ADT)
• Confirmation of adequate calcium and vitamin D status (or correction of deficiency before initiation)
• Renal function assessment (CrCl) for hypocalcemia risk stratification
• For postmenopausal osteoporosis: most MACs and commercial payers require step therapy through (or documented intolerance/contraindication to) oral bisphosphonates (alendronate, risedronate, ibandronate)
• Specialty consultation (rheumatology, endocrinology, or oncology) may be required for non-postmenopausal indications

Reference: CMS Medicare Coverage Database — LCD L33394. Verify the LCD or local coverage article applied by your MAC; some jurisdictions publish parallel articles rather than the L33394 number directly.

Commercial payer snapshot — 2026

What to document for step-therapy approval

• Oral bisphosphonate(s) tried (alendronate, risedronate, or ibandronate) with brand, dose, dates, duration
• Outcome: documented intolerance (GI, esophagitis, MSK adverse effect), inadequate response (continued T-score decline, new fracture), or contraindication (esophageal stricture, achalasia, inability to maintain upright posture, CrCl < 35 mL/min for some agents)
• For AI/ADT-induced bone loss: document the underlying cancer therapy (with start date) and DXA T-score baseline
• Pre-treatment workup: DXA T-score, calcium / vitamin D status, renal function, dental clearance

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. All four denosumab-for-osteoporosis codes refresh together each quarter.

Cross-product price comparison (Q2 2026 ASP+6%)

Coverage

Medicare Part B covers denosumab for osteoporosis (J0897 and biosimilars) under LCD L33394 and parallel MAC articles, when criteria are met. This is a buy-and-bill medical-benefit drug — NOT Part D. Most MACs cover all four denosumab-for-osteoporosis codes for FDA-approved on-label indications when paired with appropriate ICD-10 documentation.

Canonical code source: CMS HCPCS quarterly update file.

Patient assistance — one program per manufacturer Manufacturer sites verified May 2026

• Prolia (Amgen): Amgen Assist 360 / Prolia Co-pay Card for eligible commercially-insured patients; Amgen Safety Net Foundation for free drug to qualifying uninsured patients. Phone: 1-888-427-7478. Independent foundations (PAN, HealthWell) for Medicare patients — verify open funds quarterly.
• Jubbonti (Sandoz): Sandoz One Source. Phone: 1-844-726-3691. Co-pay support and PAP for free drug.
• Stoboclo (Celltrion): Celltrion Connect. Phone: 1-866-466-4046. Co-pay support and PAP for free drug.
• denosumab-bnht (Q5158): verify manufacturer assistance program at billing time.

Discontinuation rebound — multiple vertebral fracture (MVF) risk FDA label + AACE/Endocrine Society 2025

This is the dominant clinical-policy concern with denosumab. Stopping Prolia without bisphosphonate transition is associated with rapid bone-density loss and a sharp rise in vertebral fracture risk within 6–18 months.

Why the rebound happens

Denosumab’s mechanism — reversible RANK ligand inhibition — means that when the antibody clears, osteoclast activity returns sharply. Bone resorption markers exceed pre-treatment levels for several months, and bone-density gains accumulated over the treatment period are lost rapidly. In randomized discontinuation studies, vertebral fracture incidence (including multiple vertebral fractures) returns to and exceeds placebo levels within 12–18 months of the missed dose.

Practical rules for clinical and billing teams

• Do not delay the next Prolia dose beyond 7 months from the last injection without a bridge plan
• If discontinuing Prolia for any reason (intolerance, MRONJ risk, treatment-completion decision), schedule a bisphosphonate within 6 months of the last Prolia dose
• Common transition regimen: IV zoledronic acid 5 mg one time, OR oral alendronate 70 mg weekly for 12+ months — tailored to patient renal function and tolerability
• Document the transition in the chart and the discharge summary — this is a medical-malpractice exposure and a coverage-policy talking point

Other clinical danger zones

Severe hypocalcemia. Risk especially in advanced CKD (CrCl < 30 mL/min), dialysis, or vitamin D deficiency. Correct calcium before initiation. Monitor calcium baseline and within 14 days post-dose in high-risk patients.

Medication-related osteonecrosis of the jaw (MRONJ). Complete dental evaluation and any planned invasive dental procedures (extractions, implants) BEFORE initiation when feasible. Discontinue 6 months before invasive dental work if possible. MRONJ risk is lower with Prolia than with the higher-dose Xgeva regimen but is not zero.

Atypical femoral fractures (AFF). Bilateral hip / thigh / groin pain is the prodromal symptom. Imaging (X-ray) of both femurs is appropriate before continuing therapy if AFF is suspected.

Severe musculoskeletal pain. Uncommon but reported in post-marketing surveillance.

Osteoporosis treatment landscape — sequencing context AACE / Endocrine Society / ACR 2025 verified May 2026

Where Prolia sits among other osteoporosis injectables and orals. Sequencing matters — especially the discontinuation transition.

Sequencing considerations

• Prolia → bisphosphonate (mandatory transition): When stopping Prolia, transition to alendronate, risedronate, or zoledronic acid — do NOT stop without a plan
• Romosozumab → bisphosphonate or denosumab: Romosozumab is limited to 12 months of treatment; followed by an anti-resorptive to preserve gains
• Forteo / Tymlos → denosumab or bisphosphonate: PTH analogs are limited to ~24 months of lifetime use; follow with anti-resorptive to consolidate gains
• Bisphosphonate → denosumab: Common pathway when bisphosphonate is failing or poorly tolerated — the typical step-therapy sequence in commercial PA criteria

Related CareCost references

• Aldurazyme (J1931) — lysosomal storage disorder (peer drug class context: rare-disease enzyme replacement)
• Lupron Depot (J1950) — LHRH agonist for prostate cancer; the typical ADT therapy that drives the ADT-induced bone-loss indication for Prolia
• Xgeva (J0897, separate page) — same molecule, cancer-SRE indication (page in development; see disambiguation above in the meantime)

Common denials & how to fix them

Frequently asked questions

What is the difference between Prolia and Xgeva?

Prolia and Xgeva are the same molecule (denosumab) sold by Amgen as two separately FDA-approved products with different indications, doses, and dosing schedules. Prolia is 60 mg subcutaneous every 6 months for osteoporosis (postmenopausal, male, glucocorticoid-induced, AI-induced, and ADT-induced bone loss). Xgeva is 120 mg subcutaneous every 4 weeks to prevent skeletal-related events in cancer (bone metastases from solid tumors, multiple myeloma, giant-cell tumor of bone, hypercalcemia of malignancy). Both bill under the same HCPCS J0897 (1 unit = 1 mg), but with distinct ICD-10 codes, distinct biosimilars (Jubbonti for Prolia line, Wyost for Xgeva line — both denosumab-bbdz from Sandoz), and very different unit counts on the claim (60 vs. 120). Mis-billing across the line is a common audit finding.

What are the HCPCS codes for denosumab in the osteoporosis (Prolia) line?

Four codes cover the Prolia (osteoporosis) line as of Q2 2026: J0897 (reference Prolia, Amgen), Q5136 (Jubbonti — denosumab-bbdz, Sandoz; first FDA-approved Prolia biosimilar, March 2024), Q5157 (Stoboclo — denosumab-bmwo, Celltrion), and Q5158 (denosumab-bnht, newer biosimilar — verify trade name and labeler at billing time). All four codes use 1 unit = 1 mg. The same denosumab-bbdz molecule sold for the Xgeva indication is branded Wyost rather than Jubbonti.

How do I bill a Prolia injection?

Prolia for osteoporosis is billed as 60 units of J0897 (or the appropriate biosimilar Q-code) plus 96372 (therapeutic SC, non-chemo) for the administration. Append JZ to the drug line because Prolia is supplied in a single-dose prefilled syringe with no waste at standard dosing. Diagnosis links the claim to the indication: M81.0 (postmenopausal), M81.4 + Z79.52 (glucocorticoid-induced), or oncology-treatment-induced codes (Z85.3 + Z79.811 for breast cancer + AI; Z85.46 + Z79.890 for prostate cancer + ADT). Do NOT use 96401 (chemo SC) — denosumab for osteoporosis is non-chemotherapeutic.

What does CMS LCD L33394 require for Prolia coverage?

LCD L33394 (Drugs and Biologicals, applied by several MACs to osteoporosis injectables including denosumab) requires a documented diagnosis of osteoporosis (T-score ≤ -2.5 OR history of osteoporotic fracture OR multiple risk factors), confirmation of calcium and vitamin D adequacy, and demonstration of high fracture risk. Most MACs and commercial payers also require step therapy through (or documented intolerance to) oral bisphosphonates before approving denosumab for postmenopausal osteoporosis, plus baseline DXA documentation and renal function. Verify the specific LCD or local coverage article applied by your MAC.

What happens if Prolia is discontinued?

Discontinuation of Prolia is associated with a rapid loss of bone mineral density and a marked increase in vertebral fracture risk — including multiple vertebral fractures (MVF) — within 6–18 months of the last dose. The FDA label and AACE / Endocrine Society guidelines recommend that patients stopping Prolia transition to a bisphosphonate (oral alendronate or risedronate, or IV zoledronic acid) to mitigate the rebound effect. Do not stop Prolia without a planned transition. See the rebound warning section.

Why is calcium and vitamin D supplementation required with Prolia?

Denosumab inhibits RANK ligand and rapidly suppresses osteoclast-mediated bone resorption, which can cause severe hypocalcemia — especially in patients with vitamin D deficiency, chronic kidney disease (CrCl < 30 mL/min), or those on dialysis. The FDA label requires correction of pre-existing hypocalcemia BEFORE initiation and ongoing supplementation with at least 1,000 mg calcium and 400 IU vitamin D daily. Baseline calcium and 25-OH vitamin D should be measured, and calcium re-checked within 14 days post-dose in high-risk patients. Hypocalcemia (E83.51) is an absolute contraindication until corrected.

What is the Q2 2026 Medicare reimbursement for Prolia?

Q2 2026 ASP + 6% for J0897 (reference Prolia) is approximately $29.507 per 1 mg unit. A standard 60 mg dose = 60 units × $29.507 ≈ $1,770.42 before sequestration. Biosimilars are priced lower: Q5157 Stoboclo ~$26.209/unit ($1,572.54 per 60 mg dose), Q5136 Jubbonti ~$27.914/unit ($1,674.84). Q5158 denosumab-bnht is currently ~$29.797/unit, near reference. ASP refreshes quarterly — see the live snapshot above.

Are denosumab biosimilars interchangeable with Prolia?

Jubbonti (Q5136), the first FDA-approved Prolia biosimilar (March 2024), was approved with an interchangeability designation from the FDA — meaning automatic substitution at the pharmacy level is permitted under state law. Stoboclo (Q5157) and denosumab-bnht (Q5158) approvals — verify interchangeability status at billing time. UnitedHealthcare and Aetna are increasingly mandating biosimilar Q-codes over reference J0897 in 2026 commercial policies for cost reasons. Match the HCPCS to the actual NDC drawn — billing J0897 when Q5136 was administered is a denial trigger.

What FDA warnings apply to all Prolia / denosumab products?

Denosumab for osteoporosis does not carry a formal FDA Boxed Warning, but the prescribing information includes multiple high-severity Warnings & Precautions: severe hypocalcemia (correct before initiation; high risk in advanced CKD / dialysis), medication-related osteonecrosis of the jaw (MRONJ — complete invasive dental procedures before initiation when feasible), atypical femoral fractures (AFF — bilateral hip / thigh pain warrants imaging), severe musculoskeletal pain, and the discontinuation-rebound multiple vertebral fracture (MVF) risk that mandates bisphosphonate transition when stopping therapy.

Source documents

1. AAPC — HCPCS J0897 (denosumab)
   Code descriptor and crosswalk reference (covers both Prolia and Xgeva)
2. AAPC — HCPCS Q5136 (Jubbonti / Wyost — denosumab-bbdz)
   First FDA-approved Prolia/Xgeva biosimilar code descriptor (Sandoz)
3. AAPC — HCPCS Q5157 (Stoboclo — denosumab-bmwo)
   Celltrion Prolia biosimilar code descriptor
4. AAPC — HCPCS Q5158 (denosumab-bnht)
   Newer denosumab biosimilar code descriptor — verify trade name and manufacturer
5. FDA Prolia label (current revision, BLA 125320)
   Reference denosumab prescribing information for osteoporosis; W&P; rebound MVF discontinuation language
6. FDA Jubbonti label (BLA 761362, Sandoz)
   First FDA-approved Prolia biosimilar with interchangeability (March 2024)
7. FDA Stoboclo label (Celltrion)
   denosumab-bmwo Prolia biosimilar prescribing information
8. CMS Medicare Coverage Database — LCD L33394
   Drugs and Biologicals coverage for osteoporosis injectables (applied by several MACs to denosumab J0897)
9. Prolia HCP / Amgen Assist 360
   Manufacturer dosing, billing, and reimbursement guides; co-pay and Safety Net Foundation programs
10. Sandoz One Source — Jubbonti
    Sandoz biosimilar billing reference; patient assistance program (1-844-726-3691)
11. Celltrion Connect — Stoboclo
    Celltrion biosimilar billing reference; patient assistance program (1-866-466-4046)
12. AACE / ACE Postmenopausal Osteoporosis Clinical Practice Guidelines (2020, updated)
    Discontinuation-transition recommendations; sequencing across anti-resorptive and anabolic agents
13. Endocrine Society — Pharmacological Management of Osteoporosis in Postmenopausal Women (2019, updated 2020)
    Bisphosphonate-transition guidance after Prolia discontinuation
14. ACR Glucocorticoid-Induced Osteoporosis Guidelines (2022, updated)
    Coverage criteria for glucocorticoid-induced osteoporosis indication (M81.4 + Z79.52)
15. UnitedHealthcare — Denosumab Commercial Medical Drug policy
    2026 step-therapy and biosimilar-preferred designation criteria
16. Aetna Clinical Policy Bulletin — Osteoporosis
    Coverage criteria for denosumab and other osteoporosis injectables
17. CMS — Medicare Part B Drug ASP Pricing File
    Q2 2026 quarterly file (J0897, Q5136, Q5157, Q5158)
18. CMS — HCPCS quarterly update file
    Canonical HCPCS code source for denosumab family
19. CMS — JW / JZ modifier guidance
    Single-dose-container waste reporting (effective 7/1/2023)

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication of the four-product Prolia (denosumab for osteoporosis) family reference. ASP data: Q2 2026 (J0897, Q5136, Q5157, Q5158). Disambiguation from Xgeva (cancer SRE) line emphasized. LCD L33394 cited. Discontinuation rebound MVF + hypocalcemia + MRONJ + AFF warnings included. Multi-indication ICD-10 matrix (postmenopausal / glucocorticoid-induced / male / AI-induced / ADT-induced).

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File for all four denosumab-for-osteoporosis codes. Payer policies are read directly from each payer’s published medical policy documents. We do not paraphrase from billing-software vendor blogs. Where manufacturer guidance and payer policy diverge (e.g., site-of-care steering, biosimilar substitution timing), we surface the conflict rather than picking a side.

Found an error? Email hello@carecostestimate.com.